2013
DOI: 10.1038/jid.2013.191
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: We have previously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can target both the stromal and the malignant melanoma cell compartments. The replication capacity of this CRAd is driven by a 0.5-Kb SPARC promoter fragment (named F512). To improve CRAd’s efficacy, we cloned into F512 motives responsive to hypoxia (hypoxia-responsive element (HRE)) and inflammation (nuclear factor kappa B) to obtain a chimeric promoter named κBF512HRE. Using luciferase as a reporter gene, w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
19
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 15 publications
(19 citation statements)
references
References 38 publications
0
19
0
Order By: Relevance
“…In the present work, we generated a novel CRAd, AR2011, that includes a triple chimeric promoter 32 to drive the transcriptional activity of a mutated E1A. The present studies show that the in vitro lytic effect of AR2011 is blocked by soluble factors, such as antibodies present in AFs obtained from patients with ovarian cancer.…”
Section: Introductionmentioning
confidence: 81%
See 1 more Smart Citation
“…In the present work, we generated a novel CRAd, AR2011, that includes a triple chimeric promoter 32 to drive the transcriptional activity of a mutated E1A. The present studies show that the in vitro lytic effect of AR2011 is blocked by soluble factors, such as antibodies present in AFs obtained from patients with ovarian cancer.…”
Section: Introductionmentioning
confidence: 81%
“…AR2011 is a recombinant Ad derived from AdF512v1, 31 in which we cloned a triple chimeric promoter 32 upstream of the E1ΔRb gene. For this purpose, the triple chimeric promoter was amplified by PCR using the plasmid pS-2Kb512HRE-E1A as a template 32 .…”
Section: Methodsmentioning
confidence: 99%
“…Promoters of this type, such as NF-κB and HIF-1α responsive promoters have been explored in experimental gene therapy applications 19 20 21 22 23 24 25 26 , however, mono-responsive synthetic promoters are unlikely to have an activation profile that mirrors the course of a disease in its entirety, therefore, it would be logical to utilise promoters that are activated by several TFs relevant to the disease process under study. In a previous study different TFBSs were combined to create a multi-responsive synthetic promoter, but additive induction was not observed with combined stimulation 27 .…”
mentioning
confidence: 91%
“…Oncolytic adenovirus vectors, also called conditionally replicating Ads (CRAds), can specifically replicate in cancer cells and lyse them [8][9][10]. The progeny viruses are released to the neighboring cancer cells, eventually lysing the infected cancer cells.…”
Section: Introductionmentioning
confidence: 99%